BioSpace News Archive

Rarecells, Inc announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million.

ReShape Lifesciences Inc. today announced that Bart Bandy, Chief Executive Officer and President and Tom Stankovich, Chief Financial Officer of ReShape Lifesciences, will present a company overview live at VirtualInvestorConferences.com, at 2:00 pm ET on December 16th.

Good Therapeutics Strengthens Senior Management Team with Two Appointments.

Zymeworks Inc. today announced that its collaborator, BeiGene, Ltd., has dosed the first patient in South Korea in the HERIZON‑GEA‑01 trial.

CytoDyn will request FDA permission to charge HIV MDR patients under expanded access.

Albireo Pharma, Inc. today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory Board (SAB).

AnchorDx, a world-leading developer of cancer screening and early detection solutions, was accepted on December 1, 2021 , to present its “Noninvasive Lung Cancer Early Detection via Deep Methylation Representation Learning” research paper (DeepMeth) at the 36th AAAI Conference on Artificial Intelligence (AAAI-22).

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 24-week results from the global Phase 3 open-label study evaluating the safety and tolerability of investigational oral edaravone in the treatment of amyotrophic lateral sclerosis (ALS). Findings from the Phase 3 study, which is conducted by Mitsubishi.

Anatomage Inc invites educational institutions with an Anatomage Table across the United States to host regional Anatomage Tournaments through an initiative called Anatomage Tournament X.